BRDT: A Protein Involved in Bimodal Patterns and Disease (G676)

Target Name: BRDT

NCBI ID: G676

BRDT

BRDT: A Protein Involved in Bimodal Patterns and Disease

BRDT (short for Bimodal Regulatory Tissue Protein) is a protein that is expressed in various tissues throughout the body, including the brain, heart, and kidneys. It is a member of the superfamily of cytoskeletal proteins, which are involved in the structure and function of cells.BRDT has been shown to play a role in a variety of physiological processes in the body, including cell signaling, cytoskeletal organization, and inflammation.

One of the unique features of BRDT is its ability to form bimodal patterns in different cell types. This means that the same gene can be expressed in different cell types, but the levels of the protein can vary. This is important for understanding howBRDT functions and how it may be involved in various diseases.

BRDT has also been shown to be involved in a variety of diseases and conditions, including cancer, neurodegenerative diseases, and autoimmune disorders. Its role in these conditions has led to its potential as a drug target or biomarker.

One of the potential drug targets forBRDT is its role in cancer.BRDT has been shown to play a role in the development and progression of various types of cancer, including breast, ovarian, and prostate cancer. It has also been shown to promote the growth and survival of cancer cells.

In addition to its role in cancer,BRDT is also involved in neurodegenerative diseases.BRDT has been shown to contribute to the development and progression of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. It has also been shown to interact with other proteins involved in neurodegeneration, such as tau and beta-amyloid.

BRDT is also involved in autoimmune disorders.BRDT has been shown to play a role in the development and progression of autoimmune disorders, including rheumatoid arthritis and multiple sclerosis. It has also been shown to interact with other immune system proteins, such as T-cells and B-cells.

In addition to its involvement in disease,BRDT is also a potential biomarker.BRDT has been shown to be expressed in a variety of tissues and cells, including cancer cells, neurons, and immune cells. This makes it a potential target for diagnostic tests.

BRDT has also been shown to play a role in the regulation of various cellular processes, including cell signaling and cytoskeletal organization. This is important for understanding howBRDT functions and how it may be involved in various diseases.

Overall, BRDT is a protein that has the potential to be a drug target or biomarker. Its unique ability to form bimodal patterns in different cell types and its involvement in a variety of diseases and conditions make it an attractive target for research and development. Further studies are needed to fully understand its role and potential as a drug or biomarker.

Protein Name: Bromodomain Testis Associated

Functions: Testis-specific chromatin protein that specifically binds histone H4 acetylated at 'Lys-5' and 'Lys-8' (H4K5ac and H4K8ac, respectively) and plays a key role in spermatogenesis (PubMed:22464331, PubMed:22901802). Required in late pachytene spermatocytes: plays a role in meiotic and post-meiotic cells by binding to acetylated histones at the promoter of specific meiotic and post-meiotic genes, facilitating their activation at the appropriate time (PubMed:22901802). In the post-meiotic phase of spermatogenesis, binds to hyperacetylated histones and participates in their general removal from DNA (PubMed:22901802). Also recognizes and binds a subset of butyrylated histones: able to bind histone H4 butyrylated at 'Lys-8' (H4K8ac), while it is not able to bind H4 butyrylated at 'Lys-5' (H4K5ac) (By similarity). Also acts as a component of the splicing machinery in pachytene spermatocytes and round spermatids and participates in 3'-UTR truncation of specific mRNAs in post-meiotic spermatids (By similarity). Required for chromocenter organization, a structure comprised of peri-centromeric heterochromatin

The "BRDT Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about BRDT comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets